FISH for HER-2/neu in breast cancer

Standardization makes the difference!

Gokhale Sumita, Gatalica Zoran, Mohammad Amin, A. I. Rampy, Gopalrao V N Velagaleti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Context: Overexpression of HER-2/neu oncogene in breast cancer patients is correlated with disease free survival (DFS) and overall survival (OS). The most commonly used methods for the detection of HER-2/neu status are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). However, therse is a lot of controversy with regard to the best method. Most of the FISH studies chose arbitrary cut-off levels for positive results (10%) and had no validation. Aim: In order to address these issues, we designed a pilot study of 38 samples with known IHC status representing all 4 categories. Settings and Design: FISH was performed using Vysis Pathvysion™ probe. For validation, 5 cases of reduction mammoplasty were analyzed using same protocols. Results: Our results showed significant discordance between FISH and IHC. The rate of discordance was much higher in the 0, 1+, and 2+ categories compared to published literature. This could be due to the lower cut-off rates for positive amplification established by validation in our study (5.7% vs 10%). Our analysis showed that FISH positive and IHC negative patients have a poor prognosis in terms of DFS and OS compared to FISH negative and IHC negative patients. Further, our results also showed that IHC in comparison to FISH has a comparable specificity (98%), but has a very low sensitivity (46%). Conclusion: Based on these results, we consider FISH to be the gold standard for detecting HER-2/neu status in breast cancer.

Original languageEnglish (US)
Pages (from-to)152-158
Number of pages7
JournalIndian Journal of Cancer
Volume41
Issue number4
StatePublished - Oct 2004

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
Immunohistochemistry
Disease-Free Survival
Survival
Mammaplasty
Oncogenes

Keywords

  • Amplification
  • Breast cancer
  • DCIS
  • FISH
  • HER-2/neu
  • IHC
  • Pathvysion™
  • Validation

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Oncology

Cite this

Sumita, G., Zoran, G., Amin, M., Rampy, A. I., & Velagaleti, G. V. N. (2004). FISH for HER-2/neu in breast cancer: Standardization makes the difference! Indian Journal of Cancer, 41(4), 152-158.

FISH for HER-2/neu in breast cancer : Standardization makes the difference! / Sumita, Gokhale; Zoran, Gatalica; Amin, Mohammad; Rampy, A. I.; Velagaleti, Gopalrao V N.

In: Indian Journal of Cancer, Vol. 41, No. 4, 10.2004, p. 152-158.

Research output: Contribution to journalArticle

Sumita, G, Zoran, G, Amin, M, Rampy, AI & Velagaleti, GVN 2004, 'FISH for HER-2/neu in breast cancer: Standardization makes the difference!', Indian Journal of Cancer, vol. 41, no. 4, pp. 152-158.
Sumita G, Zoran G, Amin M, Rampy AI, Velagaleti GVN. FISH for HER-2/neu in breast cancer: Standardization makes the difference! Indian Journal of Cancer. 2004 Oct;41(4):152-158.
Sumita, Gokhale ; Zoran, Gatalica ; Amin, Mohammad ; Rampy, A. I. ; Velagaleti, Gopalrao V N. / FISH for HER-2/neu in breast cancer : Standardization makes the difference!. In: Indian Journal of Cancer. 2004 ; Vol. 41, No. 4. pp. 152-158.
@article{836c26230be54f73a5817fa0796b3c58,
title = "FISH for HER-2/neu in breast cancer: Standardization makes the difference!",
abstract = "Context: Overexpression of HER-2/neu oncogene in breast cancer patients is correlated with disease free survival (DFS) and overall survival (OS). The most commonly used methods for the detection of HER-2/neu status are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). However, therse is a lot of controversy with regard to the best method. Most of the FISH studies chose arbitrary cut-off levels for positive results (10{\%}) and had no validation. Aim: In order to address these issues, we designed a pilot study of 38 samples with known IHC status representing all 4 categories. Settings and Design: FISH was performed using Vysis Pathvysion™ probe. For validation, 5 cases of reduction mammoplasty were analyzed using same protocols. Results: Our results showed significant discordance between FISH and IHC. The rate of discordance was much higher in the 0, 1+, and 2+ categories compared to published literature. This could be due to the lower cut-off rates for positive amplification established by validation in our study (5.7{\%} vs 10{\%}). Our analysis showed that FISH positive and IHC negative patients have a poor prognosis in terms of DFS and OS compared to FISH negative and IHC negative patients. Further, our results also showed that IHC in comparison to FISH has a comparable specificity (98{\%}), but has a very low sensitivity (46{\%}). Conclusion: Based on these results, we consider FISH to be the gold standard for detecting HER-2/neu status in breast cancer.",
keywords = "Amplification, Breast cancer, DCIS, FISH, HER-2/neu, IHC, Pathvysion™, Validation",
author = "Gokhale Sumita and Gatalica Zoran and Mohammad Amin and Rampy, {A. I.} and Velagaleti, {Gopalrao V N}",
year = "2004",
month = "10",
language = "English (US)",
volume = "41",
pages = "152--158",
journal = "Indian Journal of Cancer",
issn = "0019-509X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - FISH for HER-2/neu in breast cancer

T2 - Standardization makes the difference!

AU - Sumita, Gokhale

AU - Zoran, Gatalica

AU - Amin, Mohammad

AU - Rampy, A. I.

AU - Velagaleti, Gopalrao V N

PY - 2004/10

Y1 - 2004/10

N2 - Context: Overexpression of HER-2/neu oncogene in breast cancer patients is correlated with disease free survival (DFS) and overall survival (OS). The most commonly used methods for the detection of HER-2/neu status are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). However, therse is a lot of controversy with regard to the best method. Most of the FISH studies chose arbitrary cut-off levels for positive results (10%) and had no validation. Aim: In order to address these issues, we designed a pilot study of 38 samples with known IHC status representing all 4 categories. Settings and Design: FISH was performed using Vysis Pathvysion™ probe. For validation, 5 cases of reduction mammoplasty were analyzed using same protocols. Results: Our results showed significant discordance between FISH and IHC. The rate of discordance was much higher in the 0, 1+, and 2+ categories compared to published literature. This could be due to the lower cut-off rates for positive amplification established by validation in our study (5.7% vs 10%). Our analysis showed that FISH positive and IHC negative patients have a poor prognosis in terms of DFS and OS compared to FISH negative and IHC negative patients. Further, our results also showed that IHC in comparison to FISH has a comparable specificity (98%), but has a very low sensitivity (46%). Conclusion: Based on these results, we consider FISH to be the gold standard for detecting HER-2/neu status in breast cancer.

AB - Context: Overexpression of HER-2/neu oncogene in breast cancer patients is correlated with disease free survival (DFS) and overall survival (OS). The most commonly used methods for the detection of HER-2/neu status are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). However, therse is a lot of controversy with regard to the best method. Most of the FISH studies chose arbitrary cut-off levels for positive results (10%) and had no validation. Aim: In order to address these issues, we designed a pilot study of 38 samples with known IHC status representing all 4 categories. Settings and Design: FISH was performed using Vysis Pathvysion™ probe. For validation, 5 cases of reduction mammoplasty were analyzed using same protocols. Results: Our results showed significant discordance between FISH and IHC. The rate of discordance was much higher in the 0, 1+, and 2+ categories compared to published literature. This could be due to the lower cut-off rates for positive amplification established by validation in our study (5.7% vs 10%). Our analysis showed that FISH positive and IHC negative patients have a poor prognosis in terms of DFS and OS compared to FISH negative and IHC negative patients. Further, our results also showed that IHC in comparison to FISH has a comparable specificity (98%), but has a very low sensitivity (46%). Conclusion: Based on these results, we consider FISH to be the gold standard for detecting HER-2/neu status in breast cancer.

KW - Amplification

KW - Breast cancer

KW - DCIS

KW - FISH

KW - HER-2/neu

KW - IHC

KW - Pathvysion™

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=13444249633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444249633&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 152

EP - 158

JO - Indian Journal of Cancer

JF - Indian Journal of Cancer

SN - 0019-509X

IS - 4

ER -